Insights Into Sequencing Treatment and Overcoming Resistance in HR-Positive/HER2-Negative ABC

Get up to date on optimal management of HR-positive/HER2-negative advanced breast cancer by watching the on-demand Webcast and downloading slides from a dynamic expert presentation on current and emerging therapies targeting CDK4/6, PI3K, AKT, mTOR, and more!
Sara Hurvitz, MD, FACP
Sara Tolaney, MD, MPH

Downloadable Slideset

Download this short highlight slideset from a live presentation on the optimal management of HR-positive/HER2-negative advanced breast cancer today.

Sara Hurvitz, MD, FACP Sara Tolaney, MD, MPH Released: July 1, 2020

Review the latest clinical data and expert guidance on leveraging CDK4/6 inhibitors for treatment of HR+/HER2- advanced breast cancer, including how to select among available agents and manage common toxicities.

Sara Hurvitz, MD, FACP Released: June 17, 2020

Get up to date on newly approved and emerging agents targeting the PI3K/AKT/mTOR pathway and ESR1 mutations in HR+/HER2- advanced breast cancer, including alpelisib, everolimus, capivasertib, SERDs, and more.

Sara Tolaney, MD, MPH Released: June 17, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?